3-Bromopyruvate and sodium citrate target glycolysis, suppress survivin, and induce mitochondrial-mediated apoptosis in gastric cancer cells and inhibit gastric orthotopic transplantation tumor growth

Oncology Reports

Volumn 35, Issue 3, 2016, Pages 1287-1296

  Wang, Ting An ^a   Zhang, Xiao Dong ^a   Guo, Xing Yu ^a   Xian, Shu Lin ^a   Lu, Yun Fei ^a  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

3 bromopyruvate; Apoptosis; Gastric cancer; Gastric orthotopic transplantation tumor; Sodium citrate

Indexed keywords

1 PHOSPHOFRUCTOKINASE; 3 BROMOPYRUVATE; ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; CASPASE 3; CITRATE SODIUM; CYTOCHROME C; FLUOROURACIL; HEXOKINASE; LACTIC ACID; PROTEIN BAX; PROTEIN BCL 2; SURVIVIN; UNCLASSIFIED DRUG; BIRC5 PROTEIN, HUMAN; BROMOPYRUVATE; CITRIC ACID; INHIBITOR OF APOPTOSIS PROTEIN; PYRUVIC ACID DERIVATIVE; REACTIVE OXYGEN METABOLITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER MORPHOLOGY; CELL CYCLE ARREST; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG MEGADOSE; ENZYME ACTIVITY; GASTRIC CANCER CELL LINE; GLYCOLYSIS; HUMAN; HUMAN CELL; LOW DRUG DOSE; MOUSE; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; STOMACH CANCER; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; DRUG EFFECTS; DRUG SCREENING; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; MITOCHONDRION; PATHOLOGY; STOMACH NEOPLASMS;

ADENOSINE TRIPHOSPHATE; ANIMALS; APOPTOSIS; CELL PROLIFERATION; CITRATES; GLYCOLYSIS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; INJECTIONS, INTRAPERITONEAL; MICE; MITOCHONDRIA; PYRUVATES; REACTIVE OXYGEN SPECIES; STOMACH NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84955489145     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.4511     Document Type: Article

References (33)

1. Yamamoto M, Sakaguchi Y, Matsuyama A, Yoshinaga K, Tsutsui S and Ishida T: Surgery after preoperative chemotherapy for patients with unresectable advanced gastric cancer. Oncology 85: 241-247, 2013.
2. Corso S, Ghiso E, Cepero V, Sierra JR, Migliore C, Bertotti A, Trusolino L, Comoglio PM and Giordano S: Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition. Mol Cancer 9: 121, 2010.
3. Vander Heiden MG, Cantley LC and Thompson CB: Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 324: 1029-1033, 2009.
4. Warburg O: The Metabolism of Tumors. Constable Press, London, 1930.
5. Liu X, Wang X, Zhang J, Lam EK, Shin VY, Cheng AS, Yu J, Chan FK, Sung JJ and Jin HC: Warburg effect revisited: An epigenetic link between glycolysis and gastric carcinogenesis. Oncogene 29: 442-450, 2010.
6. Lu Y, Zhang X, Zhang H, Lan J, Huang G, Varin E, Lincet H, Poulain L and Icard P: Citrate induces apoptotic cell death: A promising way to treat gastric carcinoma? Anticancer Res 31: 797-805, 2011.
7. Xian SL, Wei C and Lu YF: 3 BrPA inhibits proliferation of human gastric cancer cell. Chin Pract Med J 12: 78-82, 2013. (In Chinese).
8. Liu L, Gong L, Zhang Y and Li N: Glycolysis in Panc-1 human pancreatic cancer cells is inhibited by everolimus. Exp Ther Med 5: 338-342, 2013.
9. Khatri S, Yepiskoposyan H, Gallo CA, Tandon P and Plas DR: FOXO3a regulates glycolysis via transcriptional control of tumor suppressor TSC1. J Biol Chem 285: 15960-15965, 2010.
10. Floridi A, Paggi MG and Fanciulli M: Modulation of glycolysis in neuroepithelial tumors. J Neurosurg Sci 33: 55-64, 1989.
11. Nwagwu M and Opperdoes FR: Regulation of glycolysis in Trypanosoma brucei: Hexokinase and phosphofructokinase activity. Acta Trop 39: 61-72, 1982.
12. Okar DA and Lange AJ: Fructose-2,6-bisphosphate and control of carbohydrate metabolism in eukaryotes. Biofactors 10: 1-14, 1999.
13. Rider MH, Bertrand L, Vertommen D, Michels PA, Rousseau GG and Hue L: 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase: Head-to-head with a bifunctional enzyme that controls glycolysis. Biochem J 381: 561-579, 2004.
14. Gottlob K, Majewski N, Kennedy S, Kandel E, Robey RB and Hay N: Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev 15: 1406-1418, 2001.
15. Pelicano H, Martin DS, Xu RH and Huang P: Glycolysis inhibition for anticancer treatment. Oncogene 25: 4633-4646, 2006.
16. Vander Heiden MG, Plas DR, Rathmell JC, Fox CJ, Harris MH and Thompson CB: Growth factors can influence cell growth and survival through effects on glucose metabolism. Mol Cell Biol 21: 5899-5912, 2001.
17. Wang X: The expanding role of mitochondria in apoptosis. Genes Dev 15: 2922-2933, 2001.
18. Fiandalo MV and Kyprianou N: Caspase control: Protagonists of cancer cell apoptosis. Exp Oncol 34: 165-175, 2012.
19. Cohen GM: Caspases: The executioners of apoptosis. Biochem J 326: 1-16, 1997.
20. Grosse J, Warnke E, Wehland M, Pietsch J, Pohl F, Wise P, Magnusson NE, Eilles C and Grimm D: Mechanisms of apoptosis in irradiated and sunitinib-treated follicular thyroid cancer cells. Apoptosis 19: 480-490, 2014.
21. Brunelle JK and Letai A: Control of mitochondrial apoptosis by the Bcl-2 family. J Cell Sci 122: 437-441, 2009.
22. Kim H, Rafiuddin-Shah M, Tu HC, Jeffers J R, Zambetti GP, Hsieh JJ and Cheng EH: Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat Cell Biol 8: 1348-1358, 2006.
23. Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng TI, Jones DP and Wang X: Prevention of apoptosis by Bcl-2: Release of cytochrome c from mitochondria blocked. Science 275: 1129-1132, 1997.
24. Swanton E, Savory P, Cosulich S, Clarke P and Woodman P: Bcl-2 regulates a caspase-3/caspase-2 apoptotic cascade in cytosolic extracts. Oncogene 18: 1781-1787, 1999.
25. Altieri DC: Survivin and IAP proteins in cell-death mechanisms. Biochem J 430: 199-205, 2010.
26. Ambrosini G, Adida C and Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3: 917-921, 1997.
27. Ko YH, Pedersen PL and Geschwind JF: Glucose catabolism in the rabbit VX2 tumor model for liver cancer: Characterization and targeting hexokinase. Cancer Lett 173: 83-91, 2001.
28. Pedersen PL: 3-Bromopyruvate (3BP) a fast acting, promising, powerful, specific, and effective 'small molecule' anti-cancer agent taken from labside to bedside: Introduction to a special issue. J Bioenerg Biomembr 44: 1-6, 2012.
29. Shoshan MC: 3-Bromopyruvate: Targets and outcomes. J Bioenerg Biomembr 44: 7-15, 2012.
30. Killion JJ, Radinsky R and Fidler IJ: Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metastasis Rev 17: 279-284, 1998-1999.
31. Bibby MC: Orthotopic models of cancer for preclinical drug evaluation: Advantages and disadvantages. Eur J Cancer 40: 852-857, 2004.
32. Shi J, Wei PK, Zhang S, Qin ZF, Li J, Sun DZ, Xiao Y, Yu ZH, Lin HM, Zheng GJ, et al: OB glue paste technique for establishing nude mouse human gastric cancer orthotopic transplantation models. World J Gastroenterol 14: 4800-4804, 2008.
33. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC and Altieri DC: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396: 580-584, 1998.